For example, overexpression of cytokines and activation of STAT is found in the inflammation type while KRAS/BRAF mutations are more frequent in the proliferation type and associated with worse clinical outcomes.173 With regard to pCCA and dCCA, metabolic, proliferation, mesenchymal, and immune subtypes have been described.173 As the mutational landscape of CCA is further elucidated, several targeted therapeutic options have arisen of which many have been implemented into current therapeutic strategies. Here, BRAF is linked to cholangiocarcinoma.